[Simultaneous radiation- and chemotherapy (methotrexate and bleomycin) of inoperable malignant oro-facial tumors].
The overall response rate is 65% with 17% CR (medium 56 months) and 49% PR (medium 5 months). The Kaplan-Meier survival plot shows no difference between the previously treated and untreated groups, whereas the kappa 2-analysis indicates a significant advantage for patient with complete response in the previously untreated group (p less than 0.03). Between the different tumor sites and the presence or absence of lymphnodes, there was no significant difference either in survival or in the distribution of the CR, PR and P. The group with bone destruction has a significant shorter median survival time of 9 months versus 15 months in patients with no bone-involvement (p less than 0.03).
Stasler
B
B
Szepesi
T
T
Holmann
K
K
Kühböck
J
J
Mailath
G
G
Honenberg
G
G
D001761:Bleomycin / Q000627:therapeutic use; D005153:Facial Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008017:Life Expectancy; D008727:Methotrexate / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D010166:Palliative Care; D011379:Prognosis
D001761:Bleomycin; D008727:Methotrexate
Inoperabilis arctáji malignomák radio-kemoterápiával (i. a. methotrexat és bleomycin) történö egyidejü kezelése.